- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Business Development Office
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel mucolytics for the treatment of respiratory diseases
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Partnerships and collaborations
- Royalties distribution
- Start-up companies
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Leukaemia

Leukaemia is a cancer of blood cells. There are many types of leukaemia that develop from different blood cells. Our research is revealing how leukaemia develops, and advancing better treatments.
Leukaemia is the most common cancer diagnosed in children under 10 years old. With more than 4000 cases annually, it is in the top 10 cancers diagnosed in Australians each year.
Our leukaemia research
Our leukaemia research spans from basic research through to clinical trials. The major aims of our research are to:
- Discover the molecular changes that cause the development of leukaemia.
- Reveal how leukaemia cells become resistant to treatment.
- Define the similarities between normal blood cell formation and leukemia development.
- Develop and test new treatments for leukaemia, in preclinical studies and clinical trials.
What is leukaemia?
Leukaemia is a cancer of blood cells arising in the bone marrow. Healthy blood consists of many cell types that work together in a balanced system. Read more about this on our haematology research page.
In leukaemia, one type of blood cell is abnormal and builds up in numbers. This deprives other cells of the space and nutrients to function properly. Leukaemia develops in the bone marrow, where blood cells are formed. Leukaemic cells can overwhelm normal blood cell formation.
Leukaemic cells can also spread around the body, disrupting the function of other organs.
There are many types of leukaemia. The names of leukaemias can describe features of the disease and its origins. Many leukaemias’ names reflect the normal blood cell types that the leukaemic cells are closest to:
- Lymphoblastic (or lymphocytic) leukaemias resemble immune cells called lymphocytes.
- Myeloid (or myelogenous) leukaemias can have features of ‘myeloid’ immune cells such as neutrophils, or the early developmental stages of red blood cells or platelets.
Leukaemias are often further described by how rapidly the diseased cells are accumulating and worsening the disease.
- Acute leukaemias involve rapidly dividing cells that have features of immature (undeveloped) blood cells. These cells can quickly hinder normal blood cell functions such as fighting infection.
- Chronic leukaemias display a slow accumulation of cancerous cells that resemble more mature blood cells. This can occur over months or years.
In some cases, a leukaemia may begin in a chronic phase but later change, or progress, to an acute leukaemia.
Some leukaemias are very similar to other cancers of blood cells including:
Leukaemia and normal blood cell development
Blood cells develop from stem cells in the bone marrow. During development, immature cells divide and change the proteins that they produce, gradually becoming more like the mature cell. Read more about blood cell development.
Many genetic changes have been discovered that make a cell become leukaemic. Many of these changes are in genes that have a function in normal blood development. Genetic changes that contribute to leukaemia often prevent a developing blood cell from maturing.
Leukaemia risk factors
Most cases of leukaemia arise ‘spontaneously’. Occasionally people in a family may share genes that make them more likely to develop leukaemia.
Some factors increase a person’s risk of developing leukaemia. These include:
- Exposure to agents that damage DNA, such as radiation or tobacco smoke.
- Treatment with immune-suppressing medications.
- Genetic disorders, such as Down syndrome.
- Certain blood disorders, such as myelodysplastic syndrome, that can precede leukaemia.
The risk of an adult developing leukaemia increases with age. However, there are certain types of acute leukaemia that are much more common in children.
How is leukaemia treated?
Different leukaemia types respond to different treatments. Medical research has led to treatments that can cure some types of leukaemia, particularly childhood leukaemias. For some types of leukaemia, treatments may not completely eliminate the leukaemic cells, but contained them for many years. This allows the patient to live in relatively good health.
Common leukaemia treatments include:
- Chemotherapy uses medications that damage DNA and kill dividing cells.
- Radiotherapy uses radiation to kill rapidly dividing cells.
Blood stem cell transplantation is an important part of leukaemia treatment. A person with leukaemia can receive very strong chemotherapy and radiotherapy to purge leukaemic cells from their body. As well as killing the leukaemic cells, this also kills the person’s normal blood forming cells. This stops the production of new blood cells. This can be restored by a blood stem cell transplant. The blood stem cells may be from the patient themself, or from another person.
Targeted therapies
Many gene changes have been discovered that contribute to leukaemia. Often these alter the amounts of the proteins that normally regulate cell proliferation and longevity. Treatments that stop these proteins from functioning are showing promise in treating leukaemia.
Some gene changes found in leukaemia result in new proteins being formed, often from rearranged genes. These new, leukaemia-promoting proteins are attractive targets for treatment, as they are unique to leukaemia cells. This means that medications that specifically block the function of the new protein should not have any effects on normal cells.
You can read more about targeted therapies on our medicinal chemistry page.
Support for people with leukaemia
The Leukaemia Foundation provides information and support for people living with leukaemia.
WEHI researchers are not able to provide specific medical advice specific to individuals. If you have cancer and wish to find out more information about clinical trials, please visit the Australian Cancer Trials or the Australian New Zealand Clinical Trials Registry, or consult your medical specialist.
Researchers:
Super Content:
Professor Andrew Roberts and collaborators have shown that patients with an advanced form of leukaemia can achieve complete remission with a novel tablet treatment.
Starting with a landmark discovery in 1988, follow the story of how Institute research has driven development of a breakthrough anti-cancer drug.
This two-part animation from WEHI.TV explains the type of programmed cell death called apoptosis, and how the anti-cancer drug venetoclax works by forcing susceptible cells into this process.
Researchers have identified a gene mutation that causes resistance to venetoclax in some patients with CLL.
The finding could help overcome drug resistance and improve treatment options.
Dr Matthew McCormack explains his research into a common type of childhood leukaemia.